CLL patients can be distinguished into 2 categories with distinct clinical outcome, based on the presence or absence of somatic hypermutation in the immunoglobulin heavy chain variable region (IGHV) genes of the clonotypic B cell receptor (BCR). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.